Oncology

Your Article Summary

See Latest Articles

Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I–II AJCC skin melanoma: Outcome analysis from a single-institution prospectively collected database
European Journal of Cancer, 06/25/09

Mandalà M et al. - In a trial to investigate if the tumour infiltrating lymphocytes (TILs) are able to predict sentinel lymph node (SLN) positivity, disease-free survival (DFS), and overall survival (OS) in clinical stages I-II AJCC primary cutaneous melanoma (PCM), this study demonstrates that absence of TILs predicts SLN metastasis, in multivariate analysis the SLN positivity predicts DFS and OS.

• The study included consecutive pts with PCM, all diagnosed, treated, and followed up prospectively.
• Logistic regression was used to investigate the association between DFS, OS, SLN positivity, and Breslow thickness, Clark level, TIL, ulceration, lesion site, gender, regression and age.

• 1251 consecutive pts with PCM were evaluated.
• Median age was 51 with 32.2% (n = 393) of them older than 60; 44.8% of them were males.
• Of the whole series, 404 pts with primary vertical growth phase (VGP) melanoma and no clinical evidence of metastatic disease underwent SLN biopsy.
• Of these, 74 (18.8%) had a positive SLN.
• In multivariate analysis, primary melanoma on the extremities vs that on the axial locations (truncal and head/neck) and TILs (TILs vs no TILs) were predictive for lower probability of SLN involvement, while thickness (>4 mm vs 0–1 mm) was predictive for higher risk of SLN positivity.
• A multivariate stepwise analysis confirmed these results.
• The histological status of the SLN was the most significant predictor of DFS and OS.
• Pts with a negative SLN had a 5-yr DFS of 75.9%, compared with 35.2% in pts with a positive SLN and a 5-yr OS of 88.7% vs 42.9%, respectively.

Today in Dermatologic Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma
Cancer, 10/30/09

A Multimarker Prognostic Assay for Primary Cutaneous Melanoma
Clinical Cancer Research, 11/06/09

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study
British Journal of Cancer, 11/03/09

See All of Dermatologic Oncology